Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00349752 · ClinicalTrials.gov registry record · Phase 3
Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease
A Phase 3 study, sponsored by UCB Pharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 174
- Enrollment target
NCT00349752 is a Phase 3 study that was terminated before completion, run by UCB Pharma. The registered enrollment target is 174 participants.
The verdict
NCT00349752, a Phase 3 study, was terminated before completion, sponsored by UCB Pharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 174 participants
- Enrollment target
Study Summary
The current study is designed to measure the corticosteroid-sparing effect of certolizumab pegol using a defined schedule of corticosteroid tapering in subjects with moderate to severe Crohn's disease. Subjects had to be in remission (CDAI\<=150) and receiving corticosteroids at a dose no higher than 30 mg/day prednisone or equivalent during the week prior to randomization.
Interventions
- OTHER Placebo
- BIOLOGICAL certolizumab pegol 400 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00349752
The ClinicalTrials.gov registry entry for NCT00349752 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00349752 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00349752 about?
NCT00349752 is a clinical study titled "Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease". The current study is designed to measure the corticosteroid-sparing effect of certolizumab pegol using a defined schedule of corticosteroid tapering in subjects with moderate to severe Crohn's disease. Subjects had to be in remission (CDAI\<=150) and receiving corticosteroids at a dose no higher tha...
What is the current status of trial NCT00349752?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 174 participants. The study started on 2006-11. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00349752?
The interventions under investigation include: Placebo (OTHER), certolizumab pegol 400 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00349752?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.